Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
| Status: | Completed |
|---|---|
| Conditions: | Angina, Angina, Cardiology, Cardiology, Cardiology, Cardiology, Orthopedic |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 20 - 75 |
| Updated: | 10/7/2018 |
| Start Date: | May 27, 2005 |
| End Date: | October 22, 2013 |
Relationship of Diastolic Function and Functional Capacity in Hypertrophic Cardiomyopathy: A Post-Hoc Analysis of Protocols 01-H-0066 and 96-H-0144
This study will examine the relationship between certain measures of heart function and
exercise capacity in patients with hypertrophic cardiomyopathy (HCM).
Patients who participated in NHLBI studies 01-H-0006 ("Double Blind Placebo-Controlled Study
of Pirfenidone - A Novel Anti-Fibrotic Drug - in Symptomatic Patients with Hypertrophic
Cardiomyopathy Associated with Left Ventricular Diastolic Dysfunction") and 96-H-0144
("Double Blind Placebo-Controlled Study of Long-Term Effects of Angiotensin-Converting Enzyme
Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced
Left Ventricular Diastolic Dysfunction") are eligible for this study. Data from
echocardiograms and measures of left ventricular pressure obtained from patients in those
studies will be analyzed in the current study to assess their influence on exercise capacity.
No additional tests, treatments or other procedures are required.
Information from this study may help in the development of improved drug treatments for HCM.
exercise capacity in patients with hypertrophic cardiomyopathy (HCM).
Patients who participated in NHLBI studies 01-H-0006 ("Double Blind Placebo-Controlled Study
of Pirfenidone - A Novel Anti-Fibrotic Drug - in Symptomatic Patients with Hypertrophic
Cardiomyopathy Associated with Left Ventricular Diastolic Dysfunction") and 96-H-0144
("Double Blind Placebo-Controlled Study of Long-Term Effects of Angiotensin-Converting Enzyme
Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced
Left Ventricular Diastolic Dysfunction") are eligible for this study. Data from
echocardiograms and measures of left ventricular pressure obtained from patients in those
studies will be analyzed in the current study to assess their influence on exercise capacity.
No additional tests, treatments or other procedures are required.
Information from this study may help in the development of improved drug treatments for HCM.
NIH Protocols 01-H-0066, Double Blind Placebo Controlled Study of Pirfenidone A Novel
Anti-Fibrotic Drug in Symptomatic patients with Hypertrophic Cardiomyopathy (HCM) Associated
with left Ventricular Diastolic Dysfunction and 96-H-0144, Double Blind Placebo-Controlled
Study of Long-Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and
Angiotensin II Receptor Blockade (Losartan) On Genetically-Induced Left Ventricular Diastolic
Dysfunction were undertaken to assess the effect of therapeutic interventions on left
ventricular (LV) diastolic function. The relationship between baseline measures of diastolic
function as assessed by noninvasive modalities such as Doppler echocardiography and
radionuclide angiography, and qualitative and objective measures of functional capacity in
patients without LV outflow tract obstruction has not been reported. In this protocol we will
look at measures of LV geometry, relaxation and novel indices of ventricular compliance as
they may influence measures of exercise capacity. In all cases, we will use pre-existing
baseline data obtained with informed consent as part of the above protocols.
Anti-Fibrotic Drug in Symptomatic patients with Hypertrophic Cardiomyopathy (HCM) Associated
with left Ventricular Diastolic Dysfunction and 96-H-0144, Double Blind Placebo-Controlled
Study of Long-Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and
Angiotensin II Receptor Blockade (Losartan) On Genetically-Induced Left Ventricular Diastolic
Dysfunction were undertaken to assess the effect of therapeutic interventions on left
ventricular (LV) diastolic function. The relationship between baseline measures of diastolic
function as assessed by noninvasive modalities such as Doppler echocardiography and
radionuclide angiography, and qualitative and objective measures of functional capacity in
patients without LV outflow tract obstruction has not been reported. In this protocol we will
look at measures of LV geometry, relaxation and novel indices of ventricular compliance as
they may influence measures of exercise capacity. In all cases, we will use pre-existing
baseline data obtained with informed consent as part of the above protocols.
- Eligibility criteria not listed; Analysis of data from previous studies.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
